Association of the FCGR3A-158F/V gene polymorphism with the response to rituximab treatment in Spanish systemic autoimmune disease patients - PubMed (original) (raw)

. 2012 Dec;31(12):1671-7.

doi: 10.1089/dna.2012.1799. Epub 2012 Oct 17.

Ana Márquez, Cristina Lucía Dávila-Fajardo, Norberto Ortego-Centeno, José Luis Callejas Rubio, Enrique de Ramón Garrido, Julio Sánchez-Román, Francisco J García-Hernández, Raquel Ríos-Fernández, Maria Francisca González-Escribano, Maria Teresa Camps García, Maria Jesús Castillo Palma, Maria Del Mar Ayala, Javier Martín

Affiliations

• PMID: 23075294
• DOI: 10.1089/dna.2012.1799

Association of the FCGR3A-158F/V gene polymorphism with the response to rituximab treatment in Spanish systemic autoimmune disease patients

Gema Robledo et al. DNA Cell Biol. 2012 Dec.

Abstract

Rituximab is being used as treatment for systemic autoimmune diseases. The objective of this study was to determine whether the genetic variant in the Fc gamma-receptor III a (FCGR3A) gene, 158F/V, contributes to the observed variation in response to rituximab in patients with systemic autoimmune diseases. DNA samples from 132 Spanish patients with different systemic autoimmune diseases receiving rituximab were genotyped for FCGR3A-158F/V (rs396991) gene polymorphism using the TaqMan(®) allelic discrimination technology. Six months after infusion with rituximab we evaluated the response to the drug: 61% of the patients showed a complete response, partial 27% and 12% did not respond to the treatment. A statistically significant difference was observed in V allele frequency between responder (38%) and nonresponder (16%) patients (p=0.01; odds ratio [OR]=3.24, 95% confidence interval [CI] 1.17-11.1). Rituximab was also more effective in V allele carriers (94%) than in homozygous FF patients (81%): p=0.02; OR=3.96, 95% CI 1.10-17.68. These results suggest that FCGR3A-158F/V (rs396991) gene polymorphism play a role in the response to rituximab in autoimmune diseases. Validation of these findings in independent cohorts is warranted.

PubMed Disclaimer

Similar articles

• Association between functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to rituximab in patients with autoimmune diseases: a meta-analysis.
  Lee YH, Song GG. Lee YH, et al. Pharmacogenomics J. 2023 Nov;23(6):210-216. doi: 10.1038/s41397-023-00308-9. Epub 2023 May 6. Pharmacogenomics J. 2023. PMID: 37149714 Review.
• Association between -174 interleukin-6 gene polymorphism and biological response to rituximab in several systemic autoimmune diseases.
  Robledo G, Dávila-Fajardo CL, Márquez A, Ortego-Centeno N, Callejas Rubio JL, de Ramón Garrido E, Sánchez-Román J, García-Hernández FJ, Ríos-Fernández R, González-Escribano MF, Camps García MT, Castillo Palma MJ, Ayala Mdel M, Martín J. Robledo G, et al. DNA Cell Biol. 2012 Sep;31(9):1486-91. doi: 10.1089/dna.2012.1684. Epub 2012 Jun 26. DNA Cell Biol. 2012. PMID: 22734797
• Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.
  Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Cartron G, et al. Blood. 2002 Feb 1;99(3):754-8. doi: 10.1182/blood.v99.3.754. Blood. 2002. PMID: 11806974 Clinical Trial.
• IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients.
  Márquez A, Dávila-Fajardo CL, Robledo G, Rubio JL, de Ramón Garrido E, García-Hernández FJ, González-León R, Ríos-Fernández R, Barrera JC, González-Escribano MF, García MT, Palma MJ, del Mar Ayala M, Ortego-Centeno N, Martín J. Márquez A, et al. Mol Biol Rep. 2013 Aug;40(8):4851-6. doi: 10.1007/s11033-013-2583-6. Epub 2013 May 5. Mol Biol Rep. 2013. PMID: 23645042
• CD16 and CD32 Gene Polymorphisms May Contribute to Risk of Idiopathic Thrombocytopenic Purpura.
  Xu J, Zhao L, Zhang Y, Guo Q, Chen H. Xu J, et al. Med Sci Monit. 2016 Jun 18;22:2086-96. doi: 10.12659/msm.895390. Med Sci Monit. 2016. PMID: 27315784 Free PMC article. Review.

Cited by

• Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism.
  Kim HJ, Aktas O, Patterson KR, Korff S, Kunchok A, Bennett JL, Weinshenker BG, Paul F, Hartung HP, Cimbora D, Smith MA, Mittereder N, Rees WA, She D, Cree BAC. Kim HJ, et al. Ann Clin Transl Neurol. 2023 Dec;10(12):2413-2420. doi: 10.1002/acn3.51911. Epub 2023 Oct 7. Ann Clin Transl Neurol. 2023. PMID: 37804003 Free PMC article.
• Association between functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to rituximab in patients with autoimmune diseases: a meta-analysis.
  Lee YH, Song GG. Lee YH, et al. Pharmacogenomics J. 2023 Nov;23(6):210-216. doi: 10.1038/s41397-023-00308-9. Epub 2023 May 6. Pharmacogenomics J. 2023. PMID: 37149714 Review.
• Genetic Polymorphisms and the Clinical Response to Systemic Lupus Erythematosus Treatment Towards Personalized Medicine.
  Barliana MI, Afifah NN, Amalia R, Hamijoyo L, Abdulah R. Barliana MI, et al. Front Pharmacol. 2022 Mar 18;13:820927. doi: 10.3389/fphar.2022.820927. eCollection 2022. Front Pharmacol. 2022. PMID: 35370680 Free PMC article. Review.
• Pathogenicity of Proteinase 3-Anti-Neutrophil Cytoplasmic Antibody in Granulomatosis With Polyangiitis: Implications as Biomarker and Future Therapies.
  Granel J, Korkmaz B, Nouar D, Weiss SAI, Jenne DE, Lemoine R, Hoarau C. Granel J, et al. Front Immunol. 2021 Feb 18;12:571933. doi: 10.3389/fimmu.2021.571933. eCollection 2021. Front Immunol. 2021. PMID: 33679731 Free PMC article. Review.
• Understanding Inter-Individual Variability in Monoclonal Antibody Disposition.
  Thomas VA, Balthasar JP. Thomas VA, et al. Antibodies (Basel). 2019 Dec 4;8(4):56. doi: 10.3390/antib8040056. Antibodies (Basel). 2019. PMID: 31817205 Free PMC article. Review.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Medical

  • MedlinePlus Health Information